WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond

In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step. This panel will examine the complexities of these fundamental patent requirements in practice, with a special focus on polymorph patents and related areas. We'll explore how recent developments and legal decisions impact innovators and the IP landscape.

The recent Federal Circuit decision in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. and its implications for obviousness issues in polymorph patents

Strategies for evaluating novelty in polymorph and other inventions

Navigating the non-obviousness criteria for polymorphs from both prosecution and litigation perspectives

Examining the 'inventive step' requirement for polymorphs at the USPTO, EPO, and other key jurisdictions

Drawing analogies between polymorph patent strategies and biologics patent issues